Contemporary Treatment and Survival Outcomes in Mantle Cell Lymphoma: A National Real-World Analysis From REALYSA, a LYSA Cohort. (PubMed, Hematol Oncol) - Sep 22, 2026 - P=N/A | "Older patients were treated with bendamustine-rituximab (28%), R-CHOP (18%), and low-dose cytarabine (20%)...In the second-line setting (n = 72), most patients were POD24 (89%) and 56% received ibrutinib, yet outcomes remained poor (CR 24%, ORR 35%, median EFS and OS of 6.3 and 25.6 months, respectively). These findings underscore the need for improved strategies for older and high-risk patients. Retrospective landmark analyses suggest a potential association between RM and improved EFS but are limited by baseline differences between groups."
Journal • Real-world evidence • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology
|
|
Adrien Chauchet; Alain Monnereau; Aurélien Belot; Benoit Tessoulin; Bijou Fontanet; Catherine Thieblemont; Cédric Rossi; Clémentine Sarkozy; Fabrice Jardin; Fanny Cherblanc; Franck Morschhauser; François Lemonnier; Gaelle Laboure; Ghandi Damaj; Hervé Ghesquières; Julie Abraham; Krimo Bouabdallah; Laure Lebras; Loic Ysebaert; Luc Fornecker; Lucie Oberic; Ludovic Fouillet; Morgane Cheminant; Nadine Morineau; Olivier Hermine; Patrick Fogarty; Rémy Gressin; Roch Houot; Sandra Leguyader-Peyrou; Sandy Amorim; Stéphanie Guidez; Steven Le Gouill; Sylvain Carras; Thomas Gastinne
|